Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain?

Pain

Volumn 108, Issue 1-2, 2004, Pages 1-2

  Bell, Rae F ^a   Kalso, Eija ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; OPIATE; PHENCYCLIDINE; PSYCHEDELIC AGENT;

ADDICTION; ANALGESIA; BACKACHE; CANCER PAIN; CONTROLLED DRUG RELEASE; DISSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG TOLERANCE; EDITORIAL; FIBROMYALGIA; HALLUCINATION; HUMAN; MEMORY DISORDER; NEUROPATHIC PAIN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZATION; SENSATION; SIDE EFFECT; SUBSTANCE ABUSE;

EID: 1342300588     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2003.10.002     Document Type: Editorial

References (21)

1. Bell R., Eccleston C., Kalso E. Ketamine as an adjuvant to opioids in cancer pain (Cochrane review). In: The Cochrane Library. Issue 3:2003;Update Software, Oxford.
2. Birket-Smith M. Somatization and chronic pain. Acta Anaesthesiol Scand. 45:(9):2001;1114-1120.
3. Breivik H. Opioids in cancer and chronic non-cancer pain therapy - indications and controversies. Acta Anaesthesiol Scand. 45:(9):2001;1059-1066.
4. Carr D.B., Goudas L.C., Denman W.T., Brookoff D., Staats P.S., Brennen L., Green G., Albin R., Hamilton D., Rogers M.C., Firestone L., Lavin P.T., Mermelstein F. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double blind placebo-controlled crossover study. Pain. 108:2003;17-27.
5. Chaplan S.R., Malmberg A.B., Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther. 280(2):1997;829-838.
6. Eide P.K., Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade. Neurosurgery. 41:(2):1997;505-508.
7. Eide P.K., Jorum E., Stubhaug A., Bremnes J., Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain. 58:(3):1994;347-354.
8. Guignard B., Coste C., Costes H., Sessler D.I., Lebrault C., Morris W., Simonnet G., Chauvin M. Supplementing desflurane-remifentanil anesthesia with small-dose ketamine reduces perioperative opioid analgesic requirements. Anesth Analg. 95:(1):2002;103-108.
9. Hwang S.S., Chang V.T., Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 101:(1-2):2003;55-64.
10. Ilkjaer S., Petersen K.L., Brennum J., Wernberg M., Dahl J.B. Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Br J Anaesth. 76:(6):1996;829-834.
11. Kalso E., Paakari P., Stenberg I. Opioids in chronic non-cancer pain. Situation and guidelines in the Nordic countries. 1999;National Agency for Medicines, Helsinki.
12. Kalso E., Allan L., Dellemijn P.L., Faura C.C., Ilias W.K., Jensen T.S., Perrot S., Plaghki L.H., Zenz M. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 7:(5):2003;381-386.
13. Laulin J.P., Maurette P., Corcuff J.B., Rivat C., Chauvin M., Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 94:(5):2002;1263-1269.
14. Lossignol D., Gil T., Rossi C., Sosnowski M., Obiols M., Vanmeerhaeghe B., So S.M. Cancer pain: a new concept. Int Symp Supportive Care Cancer. 1992;59.
15. Luginbuhl M., Gerber A., Schnider T.W., Petersen-Felix S., Arendt-Nielsen L., Curatolo M. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg. 96:(3):2003;726-732.
16. Mao J., Price D.D., Hayes R.L., Lu J., Mayer D.J., Frenk H. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res. 605:(1):1993;164-168.
17. Moulin D.E., Iezzi A., Amireh R., Sharpe W.K.J., Boyd D., Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 347:(8995):1996;143-147.
18. Nikolajsen L., Hansen C.L., Nielsen J., Keller J., Arendt-Nielsen L., Jensen T.S. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain. 67:(1):1996;69-77.
19. Parada J.F. Treatment of pain in cancer with ketamine hydrochloride. 13th Congreso Argentino de Anestesiologia, Buenos Aires. Fed Argentina Asociac Anestesiol. 1:1971;101-105.
20. Statens Legemiddelverk/Läkemedelverket. Therapeutic guidelines: Strong opioid analgesics for chronic non-cancer pain Terapianbefaling: Sterke opioide analgetika for kronisk ikke-cancer relatert smerte. Therapeutic guidelines: Strong opioid analgesics for chronic non-cancer pain:2001;Statens Legemiddelverk/Läkemedelverket, Oslo/Stockholm.
21. Zeppetella G., O'Doherty C.A., Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 20:2000;87-92.